Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $55,798.35 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,811 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the transaction, the chief financial officer now owns 39,549 shares of the company’s stock, valued at approximately $785,047.65. This represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Friday, November 1st, Houte Hans Van sold 3,546 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.28, for a total transaction of $86,096.88.

Nurix Therapeutics Stock Down 1.5 %

NASDAQ NRIX opened at $19.71 on Friday. Nurix Therapeutics, Inc. has a 52 week low of $7.79 and a 52 week high of $29.56. The firm has a 50 day moving average of $20.09 and a two-hundred day moving average of $22.39. The stock has a market capitalization of $1.50 billion, a PE ratio of -6.82 and a beta of 2.14.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 63.38% and a negative net margin of 354.85%. On average, equities research analysts expect that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its stake in Nurix Therapeutics by 85.2% during the third quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company’s stock worth $1,531,000 after purchasing an additional 31,352 shares during the last quarter. Barclays PLC raised its holdings in Nurix Therapeutics by 77.9% during the third quarter. Barclays PLC now owns 128,344 shares of the company’s stock worth $2,884,000 after purchasing an additional 56,190 shares in the last quarter. FMR LLC lifted its position in shares of Nurix Therapeutics by 675.9% during the 3rd quarter. FMR LLC now owns 586,902 shares of the company’s stock worth $13,188,000 after buying an additional 511,256 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Nurix Therapeutics in the 3rd quarter valued at $530,000. Finally, Franklin Resources Inc. grew its position in shares of Nurix Therapeutics by 52.4% in the 3rd quarter. Franklin Resources Inc. now owns 123,101 shares of the company’s stock valued at $2,766,000 after buying an additional 42,315 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have recently issued reports on NRIX. Stephens reissued an “overweight” rating and issued a $31.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Jefferies Financial Group assumed coverage on Nurix Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $41.00 target price on the stock. JPMorgan Chase & Co. lowered their price target on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday. Royal Bank of Canada lifted their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, UBS Group began coverage on Nurix Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $35.00 target price on the stock. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $30.71.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.